来自美国、韩国和欧洲的患有和未患哮喘的COVID-19患者的特征与结局
Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe.
作者信息
Morales Daniel R, Ostropolets Anna, Lai Lana, Sena Anthony, Duvall Scott, Suchard Marc, Verhamme Katia, Rjinbeek Peter, Posada Joe, Ahmed Waheed, Alshammary Thamer, Alghoul Heba, Alser Osaid, Areia Carlos, Blacketer Clair, Burn Edward, Casajust Paula, You Seng Chan, Dawoud Dalia, Golozar Asieh, Gong Menchung, Jonnagaddala Jitendra, Lynch Kristine, Matheny Michael, Minty Evan, Nyberg Fredrik, Uribe Albert, Recalde Martina, Reich Christian, Scheumie Martijn, Shah Karishma, Shah Nigam, Schilling Lisa, Vizcaya David, Zhang Lin, Hripcsak George, Ryan Patrick, Prieto-Alhambra Daniel, Durate-Salles Talita, Kostka Kristin
机构信息
Division of Population Health and Genomics, University of Dundee, Dundee, United Kingdom of Great Britain and Northern Ireland.
Department of Public Health, University of Southern Denmark, Odense, Denmark.
出版信息
J Asthma. 2023 Jan;60(1):76-86. doi: 10.1080/02770903.2021.2025392. Epub 2022 Feb 11.
Large international comparisons describing the clinical characteristics of patients with COVID-19 are limited. The aim of the study was to perform a large-scale descriptive characterization of COVID-19 patients with asthma. We included nine databases contributing data from January to June 2020 from the US, South Korea (KR), Spain, UK and the Netherlands. We defined two cohorts of COVID-19 patients ('diagnosed' and 'hospitalized') based on COVID-19 disease codes. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes in people with asthma defined by codes and prescriptions. The diagnosed and hospitalized cohorts contained 666,933 and 159,552 COVID-19 patients respectively. Exacerbation in people with asthma was recorded in 1.6-8.6% of patients at presentation. Asthma prevalence ranged from 6.2% (95% CI 5.7-6.8) to 18.5% (95% CI 18.2-18.8) in the diagnosed cohort and 5.2% (95% CI 4.0-6.8) to 20.5% (95% CI 18.6-22.6) in the hospitalized cohort. Asthma patients with COVID-19 had high prevalence of comorbidity including hypertension, heart disease, diabetes and obesity. Mortality ranged from 2.1% (95% CI 1.8-2.4) to 16.9% (95% CI 13.8-20.5) and similar or lower compared to COVID-19 patients without asthma. Acute respiratory distress syndrome occurred in 15-30% of hospitalized COVID-19 asthma patients. The prevalence of asthma among COVID-19 patients varies internationally. Asthma patients with COVID-19 have high comorbidity. The prevalence of asthma exacerbation at presentation was low. Whilst mortality was similar among COVID-19 patients with and without asthma, this could be confounded by differences in clinical characteristics. Further research could help identify high-risk asthma patients.[Box: see text]Supplemental data for this article is available online at https://doi.org/10.1080/02770903.2021.2025392 .
描述新型冠状病毒肺炎（COVID-19）患者临床特征的大型国际比较研究有限。本研究的目的是对患有哮喘的COVID-19患者进行大规模描述性特征分析。我们纳入了9个数据库，这些数据库提供了来自美国、韩国（KR）、西班牙、英国和荷兰2020年1月至6月的数据。我们根据COVID-19疾病编码定义了两组COVID-19患者（“确诊”和“住院”）。我们对COVID-19索引日期后的患者进行随访，直至30天或死亡。我们进行了描述性分析，并报告了根据编码和处方定义的哮喘患者的特征和结局频率。确诊组和住院组分别包含666,933例和159,552例COVID-19患者。哮喘患者在就诊时的病情加重记录在1.6%-8.6%的患者中。确诊组哮喘患病率在6.2%（95%CI 5.7-6.8）至18.5%（95%CI 18.2-18.8）之间，住院组在5.2%（95%CI 4.0-6.8）至20.5%（95%CI 18.6-22.6）之间。患有COVID-19的哮喘患者合并症患病率高，包括高血压、心脏病、糖尿病和肥胖。死亡率在2.1%（95%CI 1.8-2.4）至16.9%（95%CI 13.8-20.5）之间，与无哮喘的COVID-19患者相似或更低。15%-30%的住院COVID-19哮喘患者发生急性呼吸窘迫综合征。COVID-19患者中哮喘的患病率在国际上有所不同。患有COVID-19的哮喘患者合并症患病率高。就诊时哮喘加重的患病率较低。虽然有哮喘和无哮喘的COVID-19患者死亡率相似，但这可能因临床特征的差异而混淆。进一步的研究有助于识别高危哮喘患者。[方框：见正文]本文的补充数据可在网上获取，网址为https://doi.org/10.1080/02770903.2021.2025392 。
Zotero 插件